Compare NSSC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | EVO |
|---|---|---|
| Founded | 1969 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 568.6M |
| IPO Year | 1994 | 2007 |
| Metric | NSSC | EVO |
|---|---|---|
| Price | $35.32 | $1.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $50.67 | $4.24 |
| AVG Volume (30 Days) | ★ 271.9K | 168.9K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | ★ 0.84 | N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $202,316,000.00 | N/A |
| Revenue This Year | $8.29 | N/A |
| Revenue Next Year | $8.54 | $20.47 |
| P/E Ratio | $29.97 | ★ N/A |
| Revenue Growth | ★ 11.39 | N/A |
| 52 Week Low | $33.91 | $1.33 |
| 52 Week High | $51.77 | $4.27 |
| Indicator | NSSC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 33.57 |
| Support Level | $34.51 | N/A |
| Resistance Level | $37.00 | $1.97 |
| Average True Range (ATR) | 0.84 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 33.17 | 16.25 |
NAPCO Security Technologies Inc develops, manufactures, and distributes security products, including access control systems, door security products, intrusion and fire alarm systems, alarm communication services, and video surveillance products for commercial and residential use. The Company also provides wireless communication services for intrusion and fire alarm systems. Its products include Intrusion and Access Alarm Products, Door Locking Devices and Services. The products are used for commercial, residential, institutional, industrial and governmental applications and are sold principally to independent distributors, dealers and installers of security equipment. The Company generates maximum revenue from the United States.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.